Cd300e, a transmembrane protein, is primarily expressed in myeloid cells and belongs to the CD300 glycoprotein family. Functioning as an immune-activating receptor, it has been associated with regulating oxidative stress, immune cell activation, tissue damage and repair, and lipid metabolism. Dysregulation of Cd300e has been linked to diseases like infections, immune disorders, obesity, and diabetes, highlighting its potential as a biomarker for disease diagnosis and treatment [1].

In a murine breast cancer model, exercise-downregulated Cd300E was found to have a tumor-promoting role, with upregulation in myeloma, ovarian, lung, and colorectal cancers and a correlation with poorer prognosis [2]. In mice, mCd300e, the ortholog of human Cd300e, was shown to be an immune-activating receptor that recognizes sphingomyelin and regulates non-classical and intermediate monocyte functions through FcRγ and DAP12 [3]. In a study on liver cirrhosis, CD300E+ macrophages were found to play a crucial role in promoting liver regeneration after splenectomy in decompensated cirrhotic patients [4].

In conclusion, Cd300e is a key immune-regulating molecule with diverse functions. Mouse models, such as those in breast cancer and studies on mCd300e, have provided insights into its role in cancer and immune-related processes. Its function in promoting liver regeneration also indicates its potential in treating liver-related diseases. Overall, research on Cd300e contributes to a better understanding of immune-related biological processes and disease mechanisms.